Beneficial hemodynamic effects of bosentan, a mixed ET(A) and ET(B) receptor antagonist, in portal hypertensive rats.
about
Tezosentan, an endothelin receptor antagonist, limits liver injury in endotoxin challenged cirrhotic ratsEndothelin antagonism in portal hypertensive mice: implications for endothelin receptor-specific signaling in liver disease.Hepatic stellate cells: role in microcirculation and pathophysiology of portal hypertension.Endothelin-1 contributes to maintenance of systemic but not portal haemodynamics in patients with early cirrhosis: a randomised controlled trial.Role of endothelin in fibrosis and anti-fibrotic potential of bosentan.Variceal bleeding: pharmacological therapy.Role of endothelin in systemic and portal resistance in cirrhosis.Bench-to-beside review: acute-on-chronic liver failure - linking the gut, liver and systemic circulation.Molecular pathophysiology of portal hypertension.Effects of transmitters and interleukin-10 on rat hepatic fibrosis induced by CCl4.Effects of endothelins on hepatic stellate cell synthesis of endothelin-1 during hepatic wound healing.Accelerated reversal of carbon tetrachloride-induced cirrhosis in rats by the endothelin receptor antagonist TAK-044.Role of thromboxane A2 in early BDL-induced portal hypertension.Endothelin receptor blockers reduce shunting and angiogenesis in cirrhotic rats.Regulation of the hepatic endothelin system in advanced biliary fibrosis in rats.Comparison of Two Protocols of Carbon Tetrachloride-Induced Cirrhosis in Rats - Improving Yield and Reproducibility.Hemodynamics and pharmacokinetics of tezosentan, a dual endothelin receptor antagonist, in patients with cirrhosis
P2860
Q24685743-B00671D5-A936-45E4-B9EC-7C577B070F6EQ30488861-1342DF7C-48AF-42FB-A2B8-E552C70C9914Q34559070-CDC47701-B998-44FF-8E84-A2CC173EE462Q35768938-14B572B0-5434-4198-B262-C5B0C811D03BQ36132271-689A75D4-36EA-47D7-B1E3-E11111210425Q36141427-AE790F1E-3EF1-4022-8C7F-25FE66F81106Q36564609-9565DC05-7381-484B-ACE4-6328F80723FBQ37959188-18E13B84-A1D8-4B1A-A1ED-1D805B93E5B6Q39148718-71B98FD4-4FDA-43BC-802A-896EB3D6BF2CQ43201099-2DFCA8A2-F7C9-4DE4-A4FB-0099A0FE6E87Q43994820-FF3D108F-EC15-4E65-B1CF-6BC68EEDB689Q44041359-8C6EEEE9-E005-4207-B0FD-1A2165978BBCQ44216609-DA92BF55-BC16-4A10-8C31-46AB92E00123Q48057773-CE5BAEC9-BFEE-4FD0-9A48-655F6533CB6AQ52969695-E7E1C012-93B5-4FC9-9E1A-BCCAEE6209A9Q55322529-F880D3E0-A07A-405B-A1E4-737F6710E2F2Q56925258-0C23C040-C7E9-449C-A46A-EDC34AD4F66A
P2860
Beneficial hemodynamic effects of bosentan, a mixed ET(A) and ET(B) receptor antagonist, in portal hypertensive rats.
description
1998 nî lūn-bûn
@nan
1998年の論文
@ja
1998年学术文章
@wuu
1998年学术文章
@zh-cn
1998年学术文章
@zh-hans
1998年学术文章
@zh-my
1998年学术文章
@zh-sg
1998年學術文章
@yue
1998年學術文章
@zh
1998年學術文章
@zh-hant
name
Beneficial hemodynamic effects ...... , in portal hypertensive rats.
@en
Beneficial hemodynamic effects ...... , in portal hypertensive rats.
@nl
type
label
Beneficial hemodynamic effects ...... , in portal hypertensive rats.
@en
Beneficial hemodynamic effects ...... , in portal hypertensive rats.
@nl
prefLabel
Beneficial hemodynamic effects ...... , in portal hypertensive rats.
@en
Beneficial hemodynamic effects ...... , in portal hypertensive rats.
@nl
P2093
P356
P1433
P1476
Beneficial hemodynamic effects ...... , in portal hypertensive rats.
@en
P2093
S Cailmail
P304
P356
10.1002/HEP.510280308
P407
P577
1998-09-01T00:00:00Z